Nath Bio-Genes shareholders approve ₹2 dividend, director reappointments
- Shareholders approved a final dividend of ₹2 per equity share for FY26
- All five AGM resolutions passed with over 99.98% support via remote e-voting
- Hitesh Rajnikant Purohit re-appointed as Independent Director for second five-year term
- Managing Director Satish Kagliwal's remuneration revised effective January 1, 2026
*this image is generated using AI for illustrative purposes only.
Nath Bio-Genes (India) Limited shareholders approved a final dividend of ₹2 per equity share for FY26 during the company's 33rd Annual General Meeting held on September 24, 2026.
The meeting was conducted via Video Conferencing/Other Audio-Visual Means (VC/OAVM). A total of 48 shareholders attended the virtual session, comprising 16 from the Promoter group and 32 public shareholders. The requisite quorum was present, and the proceedings were chaired by Managing Director Satish Kagliwal.
Resolutions passed
All five resolutions placed before the members were passed with the requisite majority. The votes were cast through remote e-voting, which commenced on September 21, 2026, and concluded on September 23, 2026. Mrs. Neha P Agrawal, Practising Company Secretary, served as the Scrutinizer for the voting process.
The key resolutions included the adoption of audited financial statements, declaration of dividend, and various director appointments and remuneration revisions.
| Resolution | Type | Votes in Favour (%) | Outcome |
|---|---|---|---|
| Adoption of Financial Statements | Ordinary | 99.99 | Passed |
| Declaration of Dividend (₹2/share) | Ordinary | 99.99 | Passed |
| Re-appointment of Jeevanlata Kagliwal | Ordinary | 99.98 | Passed |
| Re-appointment of Hitesh Rajnikant Purohit | Special | 99.99 | Passed |
| Revision in MD Remuneration | Ordinary | 99.98 | Passed |
Directorial changes and remuneration
The shareholders approved the re-appointment of Jeevanlata Kagliwal as a Director retiring by rotation. Additionally, Hitesh Rajnikant Purohit was re-appointed as an Independent Director for a second term of five consecutive years, effective March 30, 2027, to March 29, 2032.
An ordinary resolution was also passed to revise the remuneration of Managing Director Satish Laxminarayan Kagliwal with effect from January 1, 2026.
What the Numbers Show
Voting patterns indicate strong shareholder alignment with management decisions. Across all five resolutions, votes in favour consistently exceeded 99.98% of valid votes cast. The highest dissent was recorded on the revision of the Managing Director's remuneration, where 0.01% of votes (411 votes) were cast against the resolution by six members. In contrast, the adoption of financial statements saw only three members vote against, representing just 0.01% of the total valid votes.
Historical Stock Returns for Nath Bio-Genes
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.48% | +2.85% | -1.88% | +11.91% | -14.20% | -53.94% |
How does the revised remuneration for Managing Director Satish Kagliwal compare to industry benchmarks, and what specific performance metrics will drive future adjustments?
What strategic initiatives is Nath Bio-Genes planning to implement to sustain dividend payouts given the low attendance of only 48 shareholders at the AGM?
How might the re-appointment of Independent Director Hitesh Purohit for a second term influence the company's governance standards and long-term capital allocation strategy?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
